<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260347</url>
  </required_header>
  <id_info>
    <org_study_id>0135-0344</org_study_id>
    <nct_id>NCT04260347</nct_id>
  </id_info>
  <brief_title>SITS-IVT in Patients &gt;80 Years Study</brief_title>
  <acronym>SITS_ELDERLY</acronym>
  <official_title>Safe Implementation of Treatments in Stroke (SITS) - Intravenous Thrombolysis in Acute Ischaemic Stroke Patients Over 80 Years, SITS-IVT&gt;80 Years Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      A non-interventional post-approval study on Safe Implementation of Treatment in Stroke -
      International Stroke Thrombolysis Register (SITS-ISTR) existing data of intravenous
      recombinant tissue plasminogen Activator (rt-PA) (0.9 mg/kg) in acute ischaemic stroke
      patients over 80 years, treated according to the Summary of Product Characteristics (SmPC) in
      European countries.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 14, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Symptomatic intracerebral haemorrhage (SICH) per Safe Implementation of Thrombolysis - Stroke-Monitoring Study (SITS-MOST) definition</measure>
    <time_frame>up to 36 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality (mRS=6) within 90 days</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Death within 90 days as classified by the investigator according to cause: cerebral infarct, cerebral haemorrhage, cerebral infarct and haemorrhage unspecified, myocardial infarct, pulmonary embolism, pneumonia, other vascular cause, unknown and other cause of death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Independency as defined by mRS 0-2 within 90 days</measure>
    <time_frame>up to 90 days</time_frame>
    <description>A modified Rankin score, mRS, is used to evaluate daily activity of the patient at day 90. The scores are entered in the on-line entry form. The score 0-1 is defined as favourable outcome and 0-2 as independence of the patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient characteristics at baseline including stroke severity (NIHSS)</measure>
    <time_frame>up to 6 years</time_frame>
    <description>Baseline measurement during data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a modified Rankin score (mRS) of 0-1</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Symptomatic intracerebral haemorrhage (SICH) per European Cooperative Acute Stroke Study 2 (ECASS 2) definition</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delays of management 1: Time from onset of symptoms - start of treatment</measure>
    <time_frame>up to 4.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delays of management 2: Time from onset of symptoms - door (or as captured in the registry arrival at hospital)</measure>
    <time_frame>up to 4.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delays of management 3: Door - needle time</measure>
    <time_frame>up to 4.5 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Ischaemic Stroke</condition>
  <arm_group>
    <arm_group_label>Patients &gt;80 years after approval</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients &gt;80 years before approval</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>Patients &gt;80 years after approval</arm_group_label>
    <other_name>Actilyse®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>Patients &gt;80 years before approval</arm_group_label>
    <other_name>Actilyse®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over 80 years old presenting with acute ischaemic stroke (AIS) symptoms for which
        thrombolysis treatment was initiated within 4.5 hours after stroke onset according to the
        SmPC.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 80 years old presenting with acute ischaemic stroke symptoms for which
             thrombolysis treatment was initiated within 4.5 hours after stroke onset according to
             SmPC are included.

          -  Patients over 80 years who received thrombolysis according to SmPC for acute ischaemic
             stroke (AIS) within 4.5 hours after stroke onset during the period (approximately 3
             years) prior to July 2018 are included.

        Exclusion Criteria:

          -  Contraindication(s) to the use of IV thrombolysis per local SmPC.

          -  Documentation that the patient was enrolled or is planned to be enrolled in an
             investigational clinical trial at the time of the onset of index event and for the
             duration of the data collection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://trials.boehringeringelheim.com/trial_results/clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.
Also, Researchers can use the following link http://trials.boehringer‐ingelheim.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

